Bivalirudin for Injection 250 mg

Bivalirudin for Injection 250 mg is a powder for solution used for intravenous administration. This medication is commonly associated with anticoagulant therapy, helping to prevent blood clots. It is manufactured by Fresenius Kabi Canada Ltd.

Bivalirudin is primarily used as an anticoagulant to prevent blood clots during certain medical procedures. It is often administered intravenously to manage clotting risks in patients undergoing procedures like angioplasty or other cardiovascular interventions. The medication works by inhibiting the action of thrombin, a key enzyme in the blood clotting process.

Common effects of Bivalirudin may include bleeding at the injection site or prolonged bleeding times. Patients may also experience bruising or redness around the injection area. These effects are generally mild and temporary, but any persistent or severe reactions should be discussed with a healthcare provider.

Bivalirudin should be handled with care to avoid contamination. It is important to follow proper administration procedures to minimize the risk of bleeding. Patients with a history of bleeding disorders or those taking other anticoagulants should use this medication under medical supervision.

Bivalirudin may interact with other anticoagulants, antiplatelet drugs, and nonsteroidal anti-inflammatory drugs (NSAIDs). Alcohol consumption should be avoided as it can increase the risk of bleeding. Always inform your healthcare provider about all medications and supplements you are taking.